Get the Stockscreener App
5.65
11.16%
-0.71
After Hours:
5.78
0.13
+2.30%
Emergent Biosolutions Inc stock is traded at $5.65, with a volume of 1.97M.
It is down -11.16% in the last 24 hours and up +20.47% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$6.36
Open:
$6.31
24h Volume:
1.97M
Relative Volume:
1.65
Market Cap:
$279.29M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.3828
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+9.92%
1M Performance:
+20.47%
6M Performance:
-52.00%
1Y Performance:
+29.29%
1-Day Range:
$5.635
$6.36
1-Week Range:
$4.71
$6.70
52-Week Range:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.65 | 279.29M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions (EBS) Q1 2025 Earnings Highlight Turnaroun - GuruFocus
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2025 Earnings Call Transcript - Insider Monkey
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress - MSN
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Emergent Biosolutions: Q1 Earnings Snapshot - Norwalk Hour
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... - Yahoo
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid Revenue Challenges - GuruFocus
Earnings call transcript: Emergent BioSolutions Q1 2025 sees 656% net income rise - Investing.com Nigeria
Emergent Biosolutions earnings beat by $0.22, revenue fell short of estimates - Investing.com
Emergent Biosolutions Q1 2025 slides: turnaround progress drives profitability By Investing.com - Investing.com India
Emergent BioSolutions Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - Yahoo Finance
Emergent BioSolutions Reports 656% Net Income Surge - TipRanks
Emergent BioSolutions (EBS) Updates 2025 Financial Forecast | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) Reports Strong Q1 Revenue | EBS Stock News - GuruFocus
Emergent BioSolutions Reports First Quarter 2025 Financial Results - The Manila Times
Earnings Flash (EBS) Emergent Biosolutions Posts Q1 Adjusted EPS $0.71, vs. FactSet Est of $0.44 - marketscreener.com
Emergent BioSolutions reports shareholder vote results By Investing.com - Investing.com Nigeria
Emergent BioSolutions Stockholders Elect Directors at Meeting - TipRanks
Emergent BioSolutions reports shareholder vote results - Investing.com
Emergent BioSolutions Inc expected to post earnings of 44 cents a shareEarnings Preview - TradingView
Naloxone Market Rises with Government Initiatives to Combat Opioid Overdose | Emergent BioSolutions, Hikma, Teva - openPR.com
Emergent signs contract to supply Narcan nasal spray in Ontario - Seeking Alpha
Emergent BioSolutions Gets $65M Deal for Ontario Naloxone Program - MarketWatch
Emergent BioSolutions (EBS) Secures $65M Deal with Ontario for N - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health - The Manila Times
Emergent BioSolutions Lands Major $65M Deal: Ontario Chooses NARCAN to Fight Opioid Crisis - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
Emergent BioSolutions Inc. to Host Conference Call on Q1 2025 Financial Results - Nasdaq
Save The Date: Emergent BioSolutions Q1 2025 Earnings Conference Call Coming May 7 - Stock Titan
Lobbying Update: $920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Emergent BioSolutions launches stock repurchase program - MSN
Mile Marker Continues New Business Success With Growth-Oriented Brands - Yahoo Finance
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS - Business Wire
Emergent BioSolutions sets $50 million stock buyback plan By Investing.com - Investing.com South Africa
Emergent BioSolutions Authorizes $50 Million Stock Buyback Program - MarketScreener
Emergent BioSolutions Announces Repurchase Of Up To $50 Mln Stock, Pre-market Stock Up - Nasdaq
Emergent BioSolutions sets $50 million stock buyback plan - Investing.com
$50M Stock Buyback: Emergent BioSolutions Signals Strong Confidence in Turnaround Plan - Stock Titan
Q1 Earnings Estimate for EBS Issued By HC Wainwright - MarketBeat
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (NYSE:EBS) - Seeking Alpha
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):